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Abstract
Purpose of Review Pancreatic cystic lesions represent a growing public health dilemma, particularly as our population ages and
cross-sectional imaging becomes more sensitive. Mucinous cysts carry a clinically significant risk of developing pancreatic
cancer, which carries an extremely poor prognosis. Determining which cysts will develop cancer may be challenging, and
surgical resection of the pancreas carries significant morbidity. The goal of this paper is to review the rationale for cyst ablation
and discuss prior and current research on cyst ablation techniques and efficacy. Indications, contraindications, and factors related
to optimal patient selection are outlined.
Recent Findings Endoscopic ultrasound-guided chemoablation of pancreatic cysts has been performed in neoplastic cysts, with
varying levels of efficacy. Safety concerns arose due to the risk of pancreatitis in alcohol-based treatments; however, the most
recent data using a non-alcohol chemoablation cocktail suggests that ablation is effective without the need for alcohol, resulting in
a significantly more favorable adverse event profile.
Summary Endoscopic ultrasound-guided chemoablation of neoplastic pancreatic cysts is a promising, minimally invasive ap-
proach for treatment of cysts, with recent significant advances in safety and efficacy, suggesting that it should play a role in the
treatment algorithm.
Keywords Pancreatic cyst treatment . Pancreatic cyst ablation . Pancreatic cancer prevention
Background
Over 55,000 people will develop pancreatic cancer this year in
the United States, with 95% of cases being fatal, making it the
fourth leading cause of cancer-associated mortality [1–3]. As a
lethal malignancy with a dismal 5-year survival rate of 8%, it
has the lowest survival rate of any major cancer and is
projected to surpass colorectal cancer as the second leading
cause of cancer-related death by 2030 without breakthroughs
in prevention and therapy as we have seen in colon cancer
[1–3]. While the majority of pancreatic cancers are ductal
adenocarcinomas, approximately 20% of pancreatic cancer
develops from mucinous-type pancreatic cysts, and this
percentage may be underreported [2, 4]. Pancreatic cystic le-
sions are typically discovered incidentally on cross-sectional
imaging, occurring in approximately 2% of American adults,
with a 37% prevalence in individuals older than 80 years old
[5]. The prevalence of pancreatic cysts in the United States has
grown dramatically over the last two decades due to an aging
population and advances in imaging techniques, leading to a
public health dilemma. Although certain types of pancreatic
cysts carry little to no malignant potential, the majority are
neoplastic and includes mucinous cystic neoplasm (MCN)
and intraductal papillary mucinous neoplasm (IPMN), which
carry a clinically significant potential for malignant transfor-
mation. The natural history of a mucinous pancreatic cyst is
variable, with the overall risk of progression to pancreatic
cancer progressing to invasive cancer generally linked to its
number of high-risk features [6, 7•]. The overall risk of pro-
gression to malignancy for a mucinous cyst without high-risk
features is reported to range from 1 to 25%, and it is difficult
with current imaging techniques and cyst fluid analysis to
discern which cyst will undergo malignant transformation
[2, 8–10]. Molecular testing of cyst fluid may improve this
risk stratification but is very expensive and requires further
validation [7•, 11, 12]. Identification of a mucinous pancreatic
cyst requires the clinician and patient to choose between
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indefinite radiographic surveillance (MRI or CT) or surgical
resection, both of which have considerable limitations.
Surveillance for malignancy carries significant economic
and psychological burdens, and CT imaging includes some
degree of radiation exposure and possible nephrotoxicity. On
the other hand, surgical resection possesses a substantial risk
for serious adverse events (20–40%) and mortality (1–5%)
and still requires post-operative surveillance [13–15]. This
clinical dilemma highlights an pressing need to develop effec-
tive, less expensive, and more minimally invasive approaches
for this patient population.
In this respect, endoscopic ultrasound (EUS)-guided pan-
creatic cyst ablation has emerged as an innovative, promising
minimally invasive approach for the treatment of neoplastic
pancreatic cysts [16•, 17]. EUS-guided cyst ablation was first
demonstrated by Gan et al. where 80% alcohol was infused
into all types of pancreatic cysts (after cyst fluid aspiration)
and lavaged for 3–5 min. Patients were then followed for
6 months. Overall, a complete response rate of 35% rate was
found with a 0% risk of adverse events [18]. This study was
followed by the prospective randomized EPIC trial, which
demonstrated a 33% rate of complete cyst ablation after etha-
nol lavage with a serious adverse event rate of 4–5%
(pancreatitis) [19]. To date, ten published studies have inves-
tigated the safety and efficacy of EUS-guided pancreatic cyst
ablation using ethanol, only two of which used a randomized
design. These studies are summarized in Table 1. Although
ethanol ablation is feasible, the use of alcohol alone for pan-
creatic cyst ablation has consistently resulted in disappointing
efficacy. These poor results were illustrated most recently in a
prospective trial by Gomez et al. which found a dismal 9%
rate of complete ablation and a 4% risk of pancreatitis [22].
Overall, the clinical value of pancreatic cyst ablation with
ethanol alone is unfavorable due to the suboptimal response
and significant adverse event rates and its use as a single agent
should be abandoned.
Oh et al. added the innovative step of infusing and leaving
paclitaxel within the pancreatic cyst after ethanol lavage [23].
The addition of paclitaxel (a chemotherapeutic agent that ar-
rests cellular microtubule assembly and mitosis) has been
shown in separate trials to raise complete ablation rates to
50–79% (Table 1). The significant increase in efficacy of eth-
anol lavage plus paclitaxel infusion compared to ethanol alone
has resulted in this combination therapy becoming the pre-
ferred approach for pancreatic cyst ablation today and offering
complete ablation rates similar to that seen in other ablative
strategies in gastroenterology.
Despite this increase of efficacy, a significant limitation of
alcohol ablation with or without paclitaxel for pancreatic cyst
ablation has been the associated serious adverse events of
Table 1 Summary of EUS-guided ablation trials: ethanol, ethanol + paclitaxel, alcohol vs. gemcitabine + paclitaxel. Italics = EtOH only. Bold = EtOH
+ paclitaxel. Bold italics = EtOH + paclitaxel–gemcitabine vs. saline + paclitaxel–gemcitabine
Author, year Study type Conditions (no. of patients) Complete (CR)
or partial
resolution (PR)
Clinically significant
adverse eventsa
Gan et al. 2005 [18] Prospective (pilot) 5–80% EtOH (25) 35% CR
7% PR
0%
Dewitt et al. 2009 [20•] Prospective (RCT) 80% EtOH (25)
Saline (17)
33% CR2
0% CR
24% (4% Pancreatitis, 20% Ab pain)
12% (Ab pain)
DiMaio et al. 2011 [21] Retrospective 80% EtOH (13) 38% CR 8% (Ab pain)
Caillol et al. 2012 [19] Retrospective 99% EtOH (13) 85% CR –
Gomez et al. 2016 [22] Prospective
(pilot)
80% EtOH (23) 9% CR
44% PR
8% (4% Pancreatitis, 4% Ab pain)
Oh et al. 2008 [23] Prospective 88–99% EtOH + paclitaxel (14) 79% CR
14% PR
21% (7%Pancreatitis, 14%Ab pain)
Oh et al. 2009 [24] Prospective 99% EtOH + paclitaxel (10) 60% CR
20% PR
10% (Ab pain)
Oh et al. 2011 [25] Prospective 99% EtOH + paclitaxel (47) 62% CR
13% PR
4% (2% Pancreatitis, 2% Ab pain)
DeWitt et al. 2014 [26] Prospective 100% EtOH + paclitaxel (22) 50% CR
25% PR
23% (10% Pancreatitis, 13% Ab
pain)
Moyer et al. 2017 [27••] Prospective
(RCT)
80% EtOH paclitaxel + gemcitabine (18)
Saline + paclitaxel + gemcitabine (21)
61% CR
67% CR
28% (6% Pancreatitis, 22% Ab pain)
0%
a The overall % of adverse events described here represents the sum of AEs reported in corresponding studies (in parentheses), focusing on the two most
common AEs reported—abdominal pain and pancreatitis. However, based on reported study results, it cannot be determined whether AE categories
overlapped (e.g., whether a patient documented with pancreatitis also was a reported AE rate for abdominal pain). Other less commonly reported AEs
include intracystic bleeding (26), splenic vein obliteration (21), development of an inflammatory gastric wall cyst (27), and peritonitis (27)
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pancreatitis, peritonitis, and venous thrombosis in 0–10% of
patients [18–26, 27••]. Importantly, the mechanism for these
reported complications is believed to be secondary to the potent
inflammatory and toxic effects of alcohol on the surrounding
pancreatic parenchyma and/or neighboring vessels. The recently
published prospective, randomized, double-blind ChARM trial
evaluated a completely alcohol-free chemoablation approach
[27••]. In this study, 39 patients were randomized to saline cyst
lavage or conventional alcohol lavage with both arms then treat-
ed with a chemotherapeutic cocktail tailored specifically for pan-
creatic neoplasia (38 mg gemcitabine + 6 mg/mL paclitaxel). At
one year post-treatment, 61% of patients in the alcohol arm
achieved complete ablation compared with 67% in the alcohol-
free arm. These findings suggest that alcohol is not required for
effective pancreatic cyst ablation when a chemotherapy cocktail
specifically designed for pancreatic neoplasia is used. More im-
portantly, the rate of adverse events was significantly lower in
the alcohol-free arm (p = .01) as all minor and serious adverse
events occurred in the alcohol arm. Minor adverse events were
comprised entirely of abdominal pain, occurring in four patients
in the alcohol arm (22%) and in zero patients in the alcohol-free
arm. Collectively, these findings demonstrate that removal of
alcohol from pancreatic cyst ablation reduces adverse events to
that comparable to EUS-FNA. This is an important development,
since significantly improving the risk profile of the procedure,
while preserving its efficacy, increases the attractiveness of this
therapeutic option for patients with pancreatic cysts. This trial has
led to a larger prospective, randomized, NIH-funded, multicenter
trial using a larger sample size and several technical improve-
ments to the procedure with the results expected in four years
[28].
An important metric of the ablative approach is the
treatment durability over time. Two trials to date have
addressed this, with DeWitt et al. demonstrating the
long-term durability of pancreatic cyst ablation at
two years, showing that the majority of patients who have
an effective ablation will also have elimination of detect-
able KRAS mutations [26]. In a recent large, prospective,
follow-up study of 164 patients undergoing EUS-guided
ablation with alcohol followed by paclitaxel, Choi et al.
demonstrated that when patients achieved complete EUS-
guided pancreatic cyst ablation, 98.3% remained in remis-
sion at six-year follow-up, demonstrating an excellent du-
rable response following ablative therapy [29].
Multiple areas of uncertainty remain with this approach,
including demonstration of clinical reduction in incidence
rates of pancreatic adenocarcinoma in appropriately matched
groups, a better understanding of which patients are best treat-
ed with this approach, and an evidence-based demonstration
of the financial profile of this approach compared with a sur-
veillance and/or surgical strategy. An international white pa-
per addressing some of these issues is expected to be pub-
lished in the coming year.
Patient Selection
If EUS-guided cyst ablation is to add significant clinical
value; it should not be performed on certain high-risk
lesions which are unlikely to fully respond to treatment.
It should also be avoided in small, low-risk pancreatic
cysts with little chance of malignant progression as they
are more appropriate for routine surveillance. Ablative
strategies should be focused on cystic tumors which are
technically amendable to cyst ablation and do not show
overt signs of malignancy.
Only cysts with a likelihood of progression to malignan-
cy are currently candidates for ablation. For that reason, the
first step is to use clinical, radiographic, cytologic, and
chemical analysis by EUS-FNA to diagnose and risk strat-
ify a mucinous cyst [30]. There remains a level of uncer-
tainty in the accurate diagnosis of pancreatic cyst type in
2019, and further investigation is required to improve this
accuracy. Although 2% of the US population will have a
pancreatic cyst, the estimated prevalence of cysts > 2 cm is
estimated at only 0.8% [31]. In a recent large study evalu-
ating the long-term risk of pancreatic malignancy in pa-
tients with mucinous pancreatic cysts, 577 patients with
presumed branch duct IPMN under surveillance at
Massachusetts General Hospital were evaluated for a pri-
mary outcome of risk for malignancy over five years, com-
pared to the US population. The overall rate of development
of malignancy was 5.5%; however, of patients with cysts
1.5 cm or smaller, the overall risk of malignant transforma-
tion was 0.9%, demonstrating a very low risk for progres-
sion to malignancy for mucinous cysts < 1.5cm without
other high-risk features [32]. Additionally, it is technically
challenging to perform EUS-guided pancreatic cyst abla-
tion on cysts < 1.5 cm, as there is 0.8cc of volume within
the FNA needle itself, which prohibits meaningful ex-
change of chemotherapeutic injectate. Consequently, cyst
size ranging from 1.5 to 5 cm is the typical range of pan-
creatic cysts treated in most trials to date [16•, 17]. Cyst
morphology is an important consideration. Multiseptated
cysts present a unique challenge to ablation since treatment
must ensure that each loculation of the cyst is injected with
the ablation agent. Although cysts can appear multiseptated
on MRI-MRCP, EUS-FNA may collapse the entire cyst,
indicating communication between these individual com-
partments which may be not appreciated on cross-
sectional imaging. Most trials to date have favored uniloc-
ular to oligolocular cyst morphology and have avoided cyst
ablation in lesions with more than 4–5 discrete cell cham-
bers [16•].
When reviewing previous trials and the experience of our
centers, the recommended ideal indications and contraindica-
tions for pancreatic cyst ablation can be used to guide therapy
and are summarized as the following:
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Indications
Patients with previously identified pancreatic cysts from 1.5 to
5 cm in diameter which are consistent with mucinous-type
cysts as per guidelines [33] including indeterminate-type
cysts.
1. Contraindications:
(a) Pregnancy
(b) Similar to colonoscopy/polypectomy, the patient
should have a reasonable 3–5-year life expectancy
in order to benefit from treating a precancerous
lesion
(c) Inability to safely undergo a 30-60 min procedure
with monitored anesthesia
(d) Signs of malignancy or cytology suspicious for
malignancy
(e) Lesions which are consistent with a benign cyst by
clinical, radiographic, cytologic, and chemical anal-
y s i s ( p s eudocy s t , s e r ou s cy s t adenoma ,
lymphangioma, duplication cyst) [30].
2. Relative contraindications:
Cysts with the following high-risk features:
& Main pancreatic duct dilation > 5 mm
& Epithelial-type mural nodules
& Pathologically thick-walls or septations
& Cytology showing high-grade dysplasia.
& Signs of common bile duct or pancreatic duct obstruction,
solid mass component within or associated with a cyst,
pathologic lymphadenopathy associated with the cyst,
pancreatic duct stricture associated with tail atrophy.
& Septated cysts with > 4–5 discrete individual
compartments
& Irreversible coagulopathy, neutropenia, or thrombocyto-
penia with platelets < 30,000
& Of note, the following high-risk features are not consid-
ered to be a contraindication to ablation: growth in size,
atypical cells on cytology, or symptoms referable to the
pancreas.
We recommend that patients considered for EUS-guided
pancreatic cyst ablation should undergo a full evaluation in
the outpatient clinic setting, where their clinical, radiographic,
and endoscopic characteristics can be reviewed and explained
to the patient. Important factors to discuss include the natural
history of these tumors, areas of uncertainty, and conventional
options of surveillance and/or surgical resection as appropri-
ate. A detailed informed consent is mandatory. It is the recom-
mendation of a soon-to-be-published international white paper
that these procedures be performed by interventional
endoscopists with formal training and credentialing in EUS
and familiar with interventional EUS procedures as previously
described [34]. Additionally, these procedures should be per-
formed in a high-volume referral center in a multidisciplinary
setting.
Cyst Ablation Technique
Technical Aspects of the Procedure
Preparation for pancreatic cyst ablation is similar to stan-
dard EUS-FNA. Discussion with the anesthesiologist is
important to ensure the patient will be relatively still dur-
ing the actual ablation. If excessive movement such as
coughing, retching, or excessive respiratory movement is
felt to be likely, general anesthesia with paralysis should
be considered. The ablative agents, including any lavage
agent used and the chemotherapy infusion, (i.e., paclitaxel
or paclitaxel + gemcitabine) should be prepared prior to
the procedure. The use, ordering, delivery, and disposal
of chemotherapy ablation agents should be standardized at
each individual institution. After a full endosonographic
evaluation, the FNA needle is introduced into the center
of the cyst, carefully aspirating nearly the entire cyst con-
tents. It is our practice to use a 22-gauge FNA needle for
a cyst measuring 2–3 cm in diameter and reserving 19
gauge needles for cysts > 3 cm in diameter or previously
known to have highly viscous cyst fluid. If alcohol lavage
is used, the cyst will be then alternately filled and aspi-
rated with ethanol for 3–5 min using an amount equal to
the mucinous fluid originally aspirated. A small rim of
fluid around the needle tip is recommended at all times
to avoid damaging the cyst wall with the needle tip and
ensuring the injectate remains in the cyst (Fig. 1). If an
alcohol-free approach is used, the lavage step of the pro-
cedure may be eliminated, and instead after initial cyst
collapse, the chemoablation agent is then infused into
the cyst using an amount equal to the volume of cyst fluid
originally aspirated to refill the cyst to its original dimen-
sions. As the paclitaxel is generally quite viscous, infus-
ing the chemotherapy agent(s) typically requires high-
pressure and so an infusion apparatus, such as a syringe
strapped to a high-pressure gun or infusion device is often
used [27••]. Antibiotics are recommended as per ASGE
guidelines on the subject [33], and it has been our ap-
proach to observe these patients for an additional time
post-operatively.
Post-Operative Care and Follow-Up
DiMaio et al. demonstrated that the use of serial ablation
procedures (similar to what is done for dysplastic Barrett’s
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esophagus) is more effective than a single ablation session
for pancreatic cystic tumors [21]. The approach at our in-
stitutions utilizes 2–3 alcohol-free, gemcitabine-paclitaxel
infusions at 3-month intervals. Residual cysts at the second
and third endoscopies measuring > 15 mm are retreated if
required. This is followed by a clinic evaluation and
follow-up cross-sectional imaging at 6 and 12 months with
either enhanced MRI or CT scan to measure response and
assess for complications (Fig. 2). The definition for treat-
ment response has been standardized over multiple studies.
Baseline cyst size is measured as a volume (4/3 × π × r3
where r is cyst radius). Treatment response defined as com-
plete (≥ 95% reduction of cyst volume), partial (94–75%
reduction), or non-response (< 75% reduction) at follow-up
[16•, 25, 27••, 29]. At our programs, patients then re-enter
a surveillance program using the post-treatment measure-
ments and characteristics of the pancreatic cyst(s) to gov-
ern surveillance type and frequency as per guidelines on
this subject [6, 7•, 30].
Limitations and Areas of Uncertainty
EUS-guided pancreatic cyst ablation is a promising and
emerging approach for treating a known precursor lesion
to a lethal malignancy which has a poor prognosis and
treatment options limited to surveillance or a morbid
surgery. As an evolving approach, it has multiple areas
of uncertainty and limitations which critics have noted
[35, 36]. Several of the most common critiques are
discussed below.
1. Since ablation does actually not remove the cysts, what
evidence is there that this procedure will provide a durable
treatment response, and what if the lesion recurs?
This is similar to the previous concerns raised
regarding RFA for dysplastic Barrett’s esophagus
when critics believed that only esophagectomy (also
a morbid surgery) could assure that all dysplasia
Fig. 1 The EUS-guided cyst
ablation process: The FNA needle
is introduced into the center of the
cystic lesion. Following near
complete aspiration of mucinous
fluid from all compartments, the
cyst is then repeatedly filled and
aspirated with the lavage solution,
always leaving a small rim of
fluid around the needle tip to
prevent damaging the cyst wall.
This is followed by near complete
aspiration of the lavage agent with
subsequent filling with the
chemoablation agent(s) using the
same volume as was originally
aspirated. If an alcohol-free
ablation technique is used, there is
the option to skip the lavage step
and simply aspirate the mucinous
fluid to near total collapse,
subsequently filling the cyst with
an equal volume of chemotherapy
ablation agent(s)
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was effectively treated. To address this valid ques-
tion, DeWitt, et al. reported a prospective trial of 22
patients with mucinous cysts who underwent alcohol
ablation followed by paclitaxel infusion and follow-
ed for a median of 27 months. While only 50% of
patients achieved complete ablation, those patients
with complete ablation showed a durable effect over
a 27-month median follow-up [26]. More recently,
Choi et al. reported the results of 164 patients
who underwent EUS-guided ablation with ethanol
followed by paclitaxel. 72% of patients achieved
complete ablation and over a 6-year follow-up peri-
od, 98.3% of patients who achieved complete abla-
tion remained in complete remission at follow-up
[29]. The authors concluded this treatment approach
is an effective and durable alternative to surgery.
Overall, while no ablative strategy in gastroenterol-
ogy can be expected to be completely effective,
EUS-guided pancreatic cyst ablation appears durable
when complete ablation is achieved.
2. Ablation does not completely eliminate a patient’s risk of
developing pancreatic adenocarcinoma.
Large-scale studies demonstrating a reduction in the risk of
developing adenocarcinoma after mucinous pancreatic cyst
ablation are lacking, resulting in an area of needed research.
For example, the near complete epithelial ablation of a pro-
gressively growing 3-cm mucinous cystic neoplasm likely
significantly reduces but does not completely eliminate the
chance of developing pancreatic malignancy. Two large retro-
spective, multicenter studies in Japan demonstrated that in
patients under long-term surveillance for IPMN’s, some of
which had been treated surgically, there was a 2–4% risk of
developing a metachronous pancreatic malignancy in the re-
maining pancreas [37, 38]. Additionally, recent evidence
shows an ongoing and progressive risk of malignant transfor-
mation in IPMN’s > 1 .5cm during long-term surveillance
[32]. Consequently, whether a surgical, ablative, or surveil-
lance strategy is employed, current guidelines suggest that
long-term surveillance will be required until age and/or co-
morbidities of the patient make further surveillance unwar-
ranted. An exception would be that patients with surgically
resected mucinous cystic neoplasms (MCN variant) may
not require long-term radiographic surveillance [6, 7•].
Although it is important to critique any novel treatment
approach, it is likely not reasonable to demand that EUS-
Fig. 2 aMRI-MRCP imaging of
an 83-year-old male with a 2.7-
cm intraductal mucinous
pancreatic neoplasm (white
arrow) prior to EUS-guided
chemoablation. b Follow-up
MRI-MCRP imaging reveals no
evidence of residual cyst at
6 month follow-up evaluation
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guided ablationmust achieve complete radiologic response or
epithelial ablation in all patients to be considered a viable
treatment option. Indeed, 100% efficacy is not achievable in
otherwell-accepted ablative strategies in gastroenterology. For
example, treatment of dysplastic Barrett’s esophagus with ra-
diofrequency ablation has a known efficacy for complete
eradication of metaplasia, high- and low-grade dysplasia of
77, 81, and 90% with disease recurrence rates of 32% and a
1% risk of developing invasive carcinoma despite completing
treatment [39–41]. Recent studies report that colonoscopy is
less effective in preventing proximal colon cancer death with
impaired protection against right-sided colorectal cancer likely
due tomultiple factors, andwith a knownmiss rate of 17% for
polyps over 1 cm [42–44]. In fact, even surgical resection of
pancreatic cysts does not completely eliminate the risk of
malignancy, as a 2–4% risk of developing adenocarcinoma
would remain in the residual pancreas and would continue to
increase according to long-term follow-up studies. This sug-
gests that that any treatment strategy will require long-term
surveillance, as long as the age and co-morbidities of the
patient indicate that this is appropriate [6, 32, 33, 37, 38].
3. Pancreatic cyst ablation is dangerous.
The overall risk of adverse event rates of EUS-guided
ablation have historically ranged between 2 and 10%, with
pancreatitis, peritonitis, venous thrombosis, and abdominal
pain described. In previous trials, nearly all of these compli-
cations have been blamed on the inflammatory and toxic
effects of alcohol. However, recent randomized prospective
data indicates that alcohol is not required for effective pan-
creatic cyst ablation when a chemotherapy cocktail specifi-
cally designed for pancreatic neoplasia is used. More impor-
tantly, when alcohol is eliminated from the ablation process,
adverse events rates similar to that seen in EUS-FNA are
achieved. For this reason, evidence now indicates that EUS-
guided cyst ablation should be, in our opinion, approached
with an alcohol-free chemoablation technique, with or with-
out lavage, using paclitaxel alone or with a gemcitabine-
paclitaxel admixture. This combination has been demon-
strated to have equal efficacy and significant improvement
in safety over alcohol-based chemoablation. Additionally,
multiple trials have now shown that there are undetectable
blood levels of chemotherapy agent during the process of
pancreatic cyst ablation which was originally a concern
[27••, 45].
Conclusions
EUS-guided pancreatic cyst ablation is a promising and
emerging minimally invasive technique for the elimination
of a known precursor lesion to a lethal malignancy which
currently has poor therapeutic options limited to either a mor-
bid surgery or indefinite surveillance. Careful patient selection
is required, as is careful attention to the technical aspects of the
procedure, post-procedure evaluation, and follow-up surveil-
lance. In our experience, patients are almost universally in
favor of eliminating an appropriate neoplastic-type pancreatic
cyst and overwhelmingly favor a minimally invasive ap-
proach to do so. An emerging body of literature demonstrates
the efficacy of appropriately performed pancreatic cyst abla-
tion, a durable effect when a complete response is achieved,
and a significantly improved safety profile with an alcohol-
free protocol. Where cyst ablation fits into current treatment
algorithms should be an ongoing discussion based on efficacy,
safety, and the risk-benefit ratio unique to that patient.
Additionally, EUS-guided ablation may offer a favorable cost
profile when compared to EUS-FNA with molecular testing,
Whipple surgery, or surveillance MRI-MRCP.
There are several areas of limitations and uncertainty with this
technique. Most notably, there are no trials yet which demon-
strate that this approach objectively reduces a patient’s progres-
sion to pancreatic adenocarcinoma. This emerging technique rep-
resents an exciting treatment option for appropriately selected
patients; however, further studies are required to further develop
the efficacy, safety, and treatment indications and to define which
patients are best offered this emerging treatment option.
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